A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.
Advanced Solid Tumor
DRUG: H1710 for Injection
Incidence and severity of treatment-emergent adverse events, Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0, Up to ~ 18 months|Dose Limiting Toxicities（DLT）, Up to ~ 18 months|Maximum Tolerated Dose (MTD), Up to ~ 18 months|Recommended Phase 2 Dose (RP2D), Up to ~ 18 months
Maximum Observed Concentration(Cmax) of H1710, Blood samples will be collected to determine the Cmax of H1710., Up to ~ 18 months|Time of Maximum Concentration (Tmax)of H1710, Time to reach H1710 maximum observed concentration, Up to ~ 18 months|Area Under the Concentration (AUC) of H1710, Blood samples will be collected to determine the AUC of H1710., Up to ~ 18 months|Terminal Half life( t½) of H1710, Blood samples will be collected to determine the terminal half-life of H1710., Up to ~ 18 months|Clearance (CL) of H1710, Blood samples will be collected to determine the CL of H1710., Up to ~ 18 months|Objective Response Rate (ORR), Percentage of participants with best response of complete response (CR) or partial response (PR)., Up to ~ 18 months|Disease Control Rate(DCR), The proportion of participants with best overall response of complete response(CR) or partial response(PR) or disease stabilization(SD) after treatment., Up to ~ 18 months|Duration of Response (DOR), Time from complete response(CR) or partial response(PR) to objective disease progression or death to any cause., Up to ~ 18 months]|Progression Free Survival (PFS), The time from the start of the treatment until objective disease progression or death from any cause., Up to ~ 18 months
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of H1710 for Injection in participants with advanced solid tumors.